Technical Analysis for SAR - Sareum Holdings Plc

Grade Last Price % Change Price Change
A 222.45 2.75% 5.95
SAR closed down 3.78 percent on Monday, May 16, 2022, on 19 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Flat

Date Alert Name Type % Chg
Inside Day Range Contraction 2.75%
Wide Bands Range Expansion 2.75%
20 DMA Resistance Bearish -1.13%
Shooting Star Candlestick Bearish -1.13%
New Uptrend Bullish -1.13%
Pocket Pivot Bullish Swing Setup -1.13%
Wide Range Bar Range Expansion -1.13%
Doji - Bearish? Reversal -1.13%
Doji - Bullish? Reversal -1.13%
Multiple of Ten Bearish Other -1.13%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 10 DMA about 3 hours ago
Down 3% about 3 hours ago
Down 2% about 3 hours ago
Down 1% about 3 hours ago
Up 5% about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sareum Holdings Plc Description

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Disease Branches Of Biology Cancer Radio Diseases Drugs Biology Therapy Rtt Blood Autoimmune Diseases Disorders Cancers Skills Enzymes Medicinal Chemistry Radiotherapy Arthritis Chemotherapy Acute Myeloid Leukemia Inflammatory Disorders Kinase Leukemia Psoriasis Rheumatoid Arthritis Tyrosine Kinase

Is SAR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 345.0
52 Week Low 2.06
Average Volume 249,312
200-Day Moving Average 50.67
50-Day Moving Average 179.34
20-Day Moving Average 236.05
10-Day Moving Average 221.65
Average True Range 25.96
RSI 53.05
ADX 26.05
+DI 29.55
-DI 14.24
Chandelier Exit (Long, 3 ATRs) 267.11
Chandelier Exit (Short, 3 ATRs) 279.77
Upper Bollinger Bands 282.49
Lower Bollinger Band 189.61
Percent B (%b) 0.29
BandWidth 39.35
MACD Line 11.72
MACD Signal Line 17.95
MACD Histogram -6.2304
Fundamentals Value
Market Cap 7.07 Billion
Num Shares 3.27 Billion
EPS -0.10
Price-to-Earnings (P/E) Ratio -2165.00
Price-to-Sales 929.82
Price-to-Book 25.82
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 243.88
Resistance 3 (R3) 244.75 236.50 239.31
Resistance 2 (R2) 236.50 229.53 236.06 237.79
Resistance 1 (R1) 226.50 225.22 222.38 225.63 236.27
Pivot Point 218.25 218.25 216.19 217.81 218.25
Support 1 (S1) 208.25 211.28 204.13 207.38 196.73
Support 2 (S2) 200.00 206.97 199.56 195.21
Support 3 (S3) 190.00 200.00 193.69
Support 4 (S4) 189.13